

## List of Figures

Fig. 1. Recognized systems of Indian medicinal practice.....	6
Fig. 2. Issues that need to be addressed .....	11
Fig. 3. Displaying the percentage of plants used in different systems of medicines in India .....	12
Fig. 4. WHO guidelines for quality control methods for herbal formulations.....	22
Fig. 5. Geographic Representation of Selected Districts in Northwest Gujarat .....	53
Fig. 6. Distribution of families based on number of species.....	89
Fig. 7. Number of various plant parts and exudates in five samples.....	101
Fig. 8. Number of uses per plant parts and exudates.....	102
Fig. 9. Majoon-E-Najah (MN) Formulation .....	104
Fig. 10. Powder of Sufoof-E-Najah (SN) Formulation .....	104
Fig. 11. Powder of Sufoof-E-Chobchini (SC) Formulation.....	105
Fig. 12. Powder of Formulation 1 (F1).....	105
Fig. 13. Powder of Formulation 2 (F2).....	105
Fig. 14. Extraction yields of different extracts for Majoon-E-Najah (MN) Formulation .....	109
Fig. 15. Extraction yields of different extracts for SN, SC, F1, F2 Formulations ....	109
Fig. 16. Antibacterial activity of MN Polyherbal extracts against <i>Escherichia coli</i> .	114
Fig. 17. Antibacterial activity of MN Polyherbal extracts against <i>Bacillus megaterium</i> .....	114
Fig. 18. Antibacterial activity of Su.MN Polyherbal extracts against <i>Escherichia coli</i> .....	119
Fig. 19. Antibacterial activity of Su.MN Polyherbal extracts against <i>Bacillus megaterium</i> .....	119
Fig. 20. Antibacterial activity of SC Polyherbal extracts against <i>Escherichia coli</i> .	124
Fig. 21. Antibacterial activity of SC Polyherbal extracts against <i>Bacillus megaterium</i> .....	124
Fig. 22. Antibacterial activity of F1 Polyherbal extracts against <i>Escherichia coli</i> ..	127
Fig. 23. Antibacterial activity of F1 Polyherbal extracts against <i>Bacillus megaterium</i> .....	127
Fig. 24. Antibacterial activity of F2 Polyherbal extracts against <i>Escherichia coli</i> ...	130

Fig. 25. Antibacterial activity of F2 Polyherbal extracts against <i>Bacillus megaterium</i> .....	131
Fig. 26. Antifungal activity of MN polyherbal extracts against <i>Candida albicans</i> .	135
Fig. 27. Antifungal activity of MN polyherbal extracts against <i>Aspergillus niger</i> ..	135
Fig. 28. Antifungal activity of Su.MN polyherbal extracts against <i>Candida albicans</i> .....	138
Fig. 29. Antifungal activity of Su.MN polyherbal extracts against <i>Aspergillus niger</i> .....	138
Fig. 30. Antifungal activity of SC polyherbal extracts against <i>Candida albicans</i> ...	141
Fig. 31. Antifungal activity of SC polyherbal extracts against <i>Aspergillus niger</i> ...	141
Fig. 32. Antifungal activity of F1 polyherbal extracts against <i>Candida albicans</i> ...	144
Fig. 33. Antifungal activity of F1 polyherbal extracts against <i>Aspergillus niger</i> ....	144
Fig. 34. Antifungal activity of F2 polyherbal extracts against <i>Candida albicans</i> ...	147
Fig. 35. Antifungal activity of F2 polyherbal extracts against <i>Aspergillus niger</i> ....	147
Fig. 36. DPPH radical scavenging activity (RSA), represented by percentage of inhibition, of the three different extracts of MN formulation: Aqueous (AQ), Hydroalcoholic (HA), Ethanolic (ET) compared to ascorbic acid (AS). .....	150
Fig. 37. Non-linear regression curves of MN formulation for three extracts (Aqueous (AQ), Hydroalcoholic (HA), Ethanolic (ET)), compared with standard Ascorbic acid (AS). .....	150
Fig. 38. DPPH radical scavenging activity (RSA), represented by percentage of inhibition, of the three different extracts of Su. MN formulation: Aqueous (AQ), Hydroalcoholic (HA), Ethanolic (ET) compared to ascorbic acid (AS). .....	152
Fig. 39. Non-linear regression curves of Su.MN formulation for three extracts (Aqueous (AQ), Hydroalcoholic (HA), Ethanolic (ET)), compared with standard Ascorbic acid (AS). .....	152
Fig. 40. DPPH radical scavenging activity (RSA), represented by percentage of inhibition, of the three different extracts of SC formulation: Aqueous (AQ), Hydroalcoholic (HA), Ethanolic (ET) compared to ascorbic acid (AS). .....	154
Fig. 41. Non-linear regression curves of SC formulation for three extracts (Aqueous (AQ), Hydroalcoholic (HA), Ethanolic (ET)), compared with standard Ascorbic acid (AS). .....	154

Fig. 42. DPPH radical scavenging activity (RSA), represented by percentage of inhibition, of the three different extracts of F1 formulation: Aqueous (AQ), Hydroalcoholic (HA), Ethanolic (ET) compared to ascorbic acid (AS). .....	155
Fig. 43. Non-linear regression curves of F1 formulation for three extracts (Aqueous (AQ), Hydroalcoholic (HA), Ethanolic (ET)), compared with standard Ascorbic acid (AS). .....	156
Fig. 44. DPPH radical scavenging activity (RSA), represented by percentage of inhibition, of the three different extracts of F2 formulation: Aqueous (AQ), Hydroalcoholic (HA), Ethanolic (ET) compared to ascorbic acid (AS). .....	157
Fig. 45. Non-linear regression curves of F2 formulation for three extracts (Aqueous (AQ), Hydroalcoholic (HA), Ethanolic (ET)), compared with standard Ascorbic acid (AS). .....	157
Fig. 46. Total phenolic content for standard gallic acid .....	159
Fig. 47. Total flavonoid content for standard quercetin .....	160
Fig. 48. Total phenolic and total flavonoid content of MN polyherbal extracts .....	161
Fig. 49. Total phenolic and total flavonoid content of SN polyherbal extracts .....	162
Fig. 50. Total Phenolic Content and Total Flavonoid Content of SC Polyherbal Extracts .....	164
Fig. 51. Total Phenolic Content and Total Flavonoid Content of F1 Polyherbal Extracts .....	165
Fig. 52. Total Phenolic Content and Total Flavonoid Content of F2 Polyherbal Extracts .....	166
Fig. 53. Pearson's Correlation analysis between Phytochemical Content and Invitro Pharmacological activities of MN Polyherbal Extracts.....	169
Fig. 54. Pearson's Correlation analysis between Phytochemical Content and Invitro Pharmacological activities of Su. MN Polyherbal Extracts.....	171
Fig. 55. Pearson's Correlation analysis between Phytochemical Content and Invitro Pharmacological Activities of SC Polyherbal Extracts .....	173
Fig. 56. Pearson's Correlation analysis between Phytochemical Content and Invitro Pharmacological Activities of F1 Polyherbal Extracts.....	175
Fig. 57. Pearson's Correlation analysis between Phytochemical Content and Invitro Pharmacological Activities of F2 Polyherbal Extracts.....	177
Fig. 58. HPTLC Fingerprinting of Formulation 1 (F1) Before Derivatization.....	180
Fig. 59. HPTLC Fingerprinting of Formulation 1 (F1) After Derivatization .....	180

Fig. 60. 3D densitogram of all tracks at 254 nm (Before Derivatization). .....	181
Fig. 61. Track-wise Densitograms of Formulation 1 (F1) at 254 nm (Before Derivatization).....	186
Fig. 62. 3D densitogram of all tracks at 254 nm (Before Derivatization). .....	187
Fig. 63. Track-wise Densitograms of Formulation 1 (F1) at 366 nm (Before Derivatization).....	191
Fig. 64. Schematic Representation of Rf Values of All Tracks for Formulation 1 (F1) at 254 nm (Before Derivatization).....	192
Fig. 65. Schematic Representation of Rf Values of All Tracks for Formulation 1 (F1) at 366 nm (Before Derivatization).....	193
Fig. 66. HPTLC Fingerprinting of Formulation 2 (F2) Before Derivatization .....	195
Fig. 67. HPTLC Fingerprinting of Formulation 2 (F2) After Derivatization .....	195
Fig. 68. Track-wise densitograms of Formulation 1 (F1) at 366 nm (Before Derivatization).....	196
Fig. 69. Track-wise Densitograms of Formulation 2 (F2) at 254 nm (Before Derivatization).....	202
Fig. 70. 3D Densitogram of all tracks at 366 nm (Before Derivatization). .....	203
Fig. 71. Track-wise densitograms of Formulation 2 (F2) at 366 nm (Before Derivatization).....	208
Fig. 72. Schematic Representation of Rf Values of All Tracks for Formulation 2 (F2) at 254 nm (Before Derivatization).....	209
Fig. 73. Schematic Representation of Rf Values of All Tracks for Formulation 2 (F2) at 366 nm (Before Derivatization).....	210
Fig. 74. Schematic Representation of Classification of Major Metabolites in the Ethanol Extract (Formulation 1) Identified by HR-LCMS QTOF in Positive ESI Mode. ....	305
Fig. 75. Schematic Representation of Classification of Major Metabolites in the Ethanol Extract (Formulation 1) Identified by HR-LCMS QTOF in Negative ESI Mode. ....	306
Fig. 76. Schematic Representation of Classification of Major Metabolites in the Ethanol Extract (Formulation 2) Identified by HR-LCMS QTOF in Positive ESI Mode. ....	307

Fig. 77. Schematic Representation of Classification of Major Metabolites in the Ethanol Extract (Formulation 2) Identified by HR-LCMS QTOF in Negative ESI Mode. .....	308
Fig. 78. HR-LCMS Chromatogram of the Ethanolic Extract of Formulation 1 (F1)	309
Fig. 79. HR-LCMS Chromatogram of the Ethanolic Extract of Formulation 2 (F2)	310
Fig. 80. Ratio of Plant Parts Used per Family.....	311
Fig. 81. Heat Map of Families and Plant Parts Used Based on Calculated Frequency .....	312